Fig. 5: Efficacy of TM4SF1 CAR T cells in vivo and in vitro. | Nature Communications

Fig. 5: Efficacy of TM4SF1 CAR T cells in vivo and in vitro.

From: Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expression

Fig. 5

A Quantification of in vitro TM4SF1-CAR1 and CAR2 activity against bladder cancer cell lines using IncuCyte co-culture assay with 1:1 effector:target cell ratio. B In vitro co-culture assays comparing CAR activity (2:1 effector:target cell ratio) in UMUC3 cell lines with and without CRISPR-mediated TM4SF1 knockout (N = 1 replicate per condition, 5 conditions per experiment). C Evaluation of CAR1 tumor-killing efficacy in an in vivo xenograft model using UMUC3 (N = 9 mice) and 253JBV (N = 10 mice) cell lines. Data are presented as mean values ± standard error bars. D Kaplan–Meier survival analysis of CAR1 treated and untreated mice with UMUC3 (N = 9 mice) and 253JBV (N = 10 mice) tumors. E:T Effector:Target, UTD untransduced, CAR chimeric antigen receptor.

Back to article page